Benefit of adjuvant dabrafenib, trametinib persists in melanoma

Source: Medical Xpress, September 2020

Reinhard Dummer, M.D., from the University Hospital Zurich Skin Cancer Center, and colleagues randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of either oral dabrafenib plus trametinib or two matched placebos.

The five-year results for relapse-free survival and survival without distant metastasis (with distant metastasis as the site of the first relapse) were reported.

Patients were followed for a minimum of 59 months. The researchers found that at five years, the percentages of patients who were alive without relapse were 52 and 36 percent for dabrafenib plus trametinib and placebo, respectively (hazard ratio for relapse or death, 0.51).